BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Growth in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the recipient of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 688,400 shares, a growth of 28.7% from the November 15th total of 534,800 shares. Currently, 2.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 5,250,000 shares, the days-to-cover ratio is presently 0.1 days.

BriaCell Therapeutics Price Performance

BCTX remained flat at $0.66 during trading on Friday. The company’s stock had a trading volume of 2,234,086 shares, compared to its average volume of 1,642,969. The company has a market capitalization of $23.88 million, a PE ratio of -0.56 and a beta of 1.46. The company’s 50 day moving average price is $0.84 and its 200 day moving average price is $0.88. BriaCell Therapeutics has a 52-week low of $0.46 and a 52-week high of $5.97.

BriaCell Therapeutics (NASDAQ:BCTX) last released its quarterly earnings results on Monday, October 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.45. As a group, analysts predict that BriaCell Therapeutics will post -1.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of BriaCell Therapeutics in a report on Thursday.

Hedge Funds Weigh In On BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned approximately 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. 15.42% of the stock is currently owned by institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.